Hedgehog信号通路及其抑制剂在癌症中的研究进展  

Research progress of Hedgehog signaling pathway and its inhibitors in cancers

作　　者：王岛[1] Alan K Chang 伍会健[1] 

机构地区：[1]大连理工大学生命科学与技术学院,大连116024

出　　处：《生命的化学》2014年第1期98-103,共6页Chemistry of Life

基　　金：国家自然科学基金项目(31271500);国家重点基础研究发展计划("973"计划)(2011CB504201)

摘　　要：Hedgehog(HH)信号通路在胚胎发育和器官形成中发挥重要作用。当该通路中成员发生异常如patched(PTCH)发生缺失或突变,smoothened(SMO)发生突变,Gli异常扩增或者蛋白质稳定性增加等,都会导致该通路异常激活,并诱导如基底细胞癌、成神经管细胞瘤等癌症发生。因此阻断HH信号通路是应用于癌症治疗的一个有效手段。目前以HH信号通路不同成员为靶点已开发出多种HH信号通路小分子抑制剂,其中以HH信号通路上游成员为靶点的抑制剂最多。在今后的研究中,应该更加注重于以HH信号通路下游为靶点,开发更加有效的抗癌药物。The Hedgehog （HH） pathway is a conserved signaling pathway essential for embryonic development and organ formation. It can be abnormally activated by the loss or mutation of Patched （PTCH）, mutation of Smoothened （SMO）, or abnormal amplification of Glil and increased Glil protein stability, resulting in the occurrence of cancers, such as basal cell carcinoma and medulloblastoma. Thus targeting elements of the HH pathway may offer an effective therapeutic strategy in the fight against certain cancers. Many small-molecule inhibitors that target different components of the HH pathway have already been discovered, and most of these seem to target elements upstream of the HH pathway. The search for small molecules that may target elements downstream of the HH pathway and their development into potential and effective anti-cancer drugs may constitute a major part of future research into HH signaling.

关 键 词：HEDGEHOG 抑制剂 癌症 

分 类 号：R730.5[医药卫生—肿瘤]